Mein Warenkorb

Syndecan-1

Syndecan-1 Molekülinformation

Englischer NameSyndecan-1Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2Target-AliasSyndecan Proteoglycan 1,CD138 Antigen,SYND1,SDC,Heparan Sulfate Proteoglycan Fibroblast Growth Factor Receptor,Syndecan,CD138,Syndecan-1,SDC1,Syndecan 1
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical
Englischer NameSyndecan-1
Target-AliasSyndecan Proteoglycan 1,CD138 Antigen,SYND1,SDC,Heparan Sulfate Proteoglycan Fibroblast Growth Factor Receptor,Syndecan,CD138,Syndecan-1,SDC1,Syndecan 1
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical

Syndecan-1 Produktliste

  • Attribut

    Protein (5)

  • Produktbibliothek

    Online (5)

  • Spezies

    Human (5)

  • Etikett

    His Tag & Avi Tag (1)Fc Tag & Avi Tag (1)Fc Tag (1)His Tag (2)

  • Marker

    Biotin-labeled (2)Unconjugated (2)FITC Labeled (1)

Syndecan-1 Molekülhintergrund

Syndecan-1 (SYND1 or SDC1) is also known as CD antigen CD138, is a transmembrane (type I) heparan sulfate proteoglycan and is a member of the syndecan proteoglycan family. The syndecans mediate cell binding, cell signaling, and cytoskeletal organization and syndecan receptors are required for internalization of the HIV-1 tat protein. The syndecan-1 / SDC1 protein functions as an integral membrane protein and participates in cell proliferation, cell migration and cell-matrix interactions via its receptor for extracellular matrix proteins. It is a useful marker for plasma cells, but only if the cells tested are already known to be derived from blood.

Syndecan-1 Molekülalias

SDC1,Syndecan-1,CD138,SYND1,SDC

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
ATLCAR.CD138 (UNC Lineberger Comprehensive Cancer Center)Phase 1 ClinicalUnc Lineberger Comprehensive Cancer CenterImmune System Diseases; Multiple Myeloma
Details
QXL-138AMQXL-138AMPhase 1 ClinicalNammi Therapeutics IncBreast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Gastrointestinal Neoplasms; Lung Neoplasms; Multiple Myeloma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns